Analysis of cfDNA fragmentomics metrics and commercial targeted sequencing panels
Nature Communications 16, published online 2025-10-14; Europe PMC full-text JATS XML of PMC12521513 · Peer-reviewed
DOI: 10.1038/s41467-025-64153-z
The authors (University of Wisconsin) previously published first-exon fragment-size entropy on targeted panels (their reference 19) and here re-implement other groups' whole-genome fragmentomic metrics on panel exons. They state that the study compares metrics and does not produce a locked prediction model.
What this source contributed
Records in this release that cite this source. A record can cite several sources.
Results
Values as the source printed them. Compare results only under compatible protocols, datasets and metrics.
Claims
Statements this source supports, each with where in the source it was checked.
- Evidence summary: plasma ctDNA fragmentomics workflows: Summary Eight sources compare plasma cfDNA fragmentomic workflows on retrospective case-control cohorts. None is a prospective screening study and none measures clinical benefit. Cristiano et al. 2019, the DELFI developers, report 73% sensitivity (152 of 208 cancers) at a reported 98% specificity for DELFI in repeated cross-validation against 215 healthy individuals. Hou et al. 2024 re-implemented ten published fragmentation patterns and DELFI with one support vector machine each on the same cohort. They are independent of every pattern except IFS, which their corresponding author developed. In 10 x 10-fold cross-validation, pan-cancer AUC within open chromatin regions ranged from 0.8741 (fragment length) to 0.9736 (5' end motif), and their DELFI re-implementation reached 0.9575. Rankings changed on independent cohorts. On 46 lung cancers and 385 healthy individuals, with a model trained on 12 lung cancers, the end-motif model fell to AUC 0.5355 and sensitivity 0.0652 at 95% specificity, while fragment size distribution reached 0.9386 and 0.7174. Hou et al.'s supplementary pan-cancer and liver cancer sensitivities conflict with other tables of the same file and are not shown. Wang et al. 2026, the UNITE developers, stratified cancers by ichorCNA tumour fraction in pooled public and new 0.1x data that include samples of the DELFI and Jiang et al. cohorts used above. For cancers with an estimated tumour fraction of 3% or less, cross-validated AUC was 0.878 for all five features combined, 0.873 for fragment length, 0.857 for the SD of length counts, 0.736 for copy number, 0.715 for the C/T end-motif ratio and 0.651 for the short/long ratio, against 0.603 for a classifier using the ichorCNA tumour fraction alone, which detected 0.058 of these cancers at 95% specificity. For cancers with an estimated fraction above 3% and up to 10%, the ichorCNA classifier reached 0.983, above the combined model (0.962) and copy number alone (0.926). The extracted UNITE tables give sensitivity at a fixed specificity only for the ichorCNA comparator; the fragmentomic models' values are in a sheet not yet extracted. Jamshidi et al. 2022 (Cancer Cell), by the GRAIL developers, scored fragment length and fragment endpoint classifiers from 30x cfDNA whole-genome sequencing on the same CCGA substudy 1 participants as their methylation, copy-number and variant classifiers, at a 98% specificity threshold set post hoc within each set. On the validation set of 464 cancers and 362 non-cancers the fragment length classifier detected 29% (95% CI 25% to 34%) and the fragment endpoint classifier 18% (15% to 22%), against 34% for whole-genome methylation analysed double-blinded; both fragment classifiers were developed after the validation set had been unblinded, so these are not blinded validation results, and no tumour-fraction-stratified sensitivity is printed. Zeng et al. 2026 (Nature Cancer), by the cfMeDIP-seq developers, computed fragmentomic features from cfMeDIP-seq reads, which are enriched for methylated fragments rather than drawn from whole-genome sequencing, and report means over 10 fold models. On an independent paired-end validation set, a fragment-ratio classifier reached AUC 0.848 and detected 0.533 of cancers at 99% specificity, and fragment ratios combined with methylation reached 0.954 and 0.766. The validation set has 17 healthy controls, so its 99% specificity allows no false positive among them, and Li-Fraumeni syndrome carriers without current cancer count as cancers in its sensitivities. Three of the five classifiers that include end motifs scored below AUC 0.5 there, which the authors attribute to healthy controls processed with a different laboratory protocol, so validation results for all five are not shown. Helzer et al. 2025 (Nature Communications) compared twelve fragmentomic metrics adapted to targeted exon panels, including the authors' own fragment-size entropy metrics, their combination and Griffin, with one classifier and shared folds, on plasma from patients with metastatic cancer. The healthy-versus-cancer one-vs-rest AUROC ranged from 0.835 (open-chromatin entropy) to 0.989 (first-exon depth) in a UW cohort of 404 cancers and 27 healthy donors, with Griffin at 0.944, and from 0.951 to 1.000 in public GRAIL panel data from 151 cancers and 47 healthy donors. In a developer comparison on 0.1x whole-genome sequencing (Cell Reports Medicine 2026), a fragment-level language model (Fragmentia-AI) reached AUC 0.9561 on a held-out set of unstated size, against 0.9209 to 0.935 for the developers' re-implementation of DELFI features and 0.881 to 0.8863 for Griffin features under three classifiers. The same company's whole-genome model (Molecular Biomedicine 2026), on an independent test cohort of 2,952 cancers and 3,044 non-cancer controls, reached AUC 0.910 for cancers with an ichorCNA tumour fraction below 3% and detected 0.46 of them at a cutoff set to 98% specificity in training (observed test specificity 0.97); among those low-fraction cancers it detected 0.391 at stage I/II (637 of 1,628) and 0.708 at stage III/IV (345 of 487). Its tumour-fraction strata are ichorCNA estimates, no comparator was run on its cohorts, and its training cohort has the same number of non-cancer controls (1,245) as the Cell Reports Medicine cohort, so the two studies may share samples. Three of these four studies report on their authors' own method, and in the fourth the authors' own entropy metrics are among those compared. Cohorts, feature implementations, classifiers and validation designs differ, so no value is comparable across sources. (amp-20261007-ctdna-fragmentomics-source: result amp-20261007-ctdna-fragmentomics-result; ctdnafrag-20261009-source-hou2024: Table 1, P24 and P44; ctdnafrag-20261009-source-hou2024-supporting-information: Table S3; ctdnafrag-20261009-source-wang2026-data-file-s2: STATS_xgb_x1-x6 and STATS_lr; ctdnafrag-20261009-source-wang2026: Results and Methods; ctdnajam-20261010-source-jamshidi2022: Table 3 validation column and Results, cancer signal origin prediction; ctdnalit-20261011-zeng2026-source-article: Results P28-P33; ctdnalit-20261011-zeng2026-source-source-data-fig4: sheets Fig.4c and Fig.4d; ctdnalit-20261011-helzer2025-source-supplementary-information: Supplementary Tables S1 and S2, 'Normal' columns; ctdnalit-20261011-helzer2025-source-article: Results P5-P8; ctdnalit-20261011-fragmentia2026-source-document-s1: Table S5; ctdnalit-20261011-fragmentia2026-source-article: Results P39-P44; ctdnalit-20261011-fragmentiawgs2026-source-article: Results P8-P21; ctdnalit-20261011-fragmentiawgs2026-source-supplementary-material-1: Tables S1 and S4)
- related_result: ctdnalit-20261011-helzer2025-protocol-grail-full: Related result In silico mixing of GRAIL-cohort cancer and healthy reads (70% training, 30% validation; mixtures 50:50 to 1:99 at 100 M reads) showed all metrics losing AUROC as ctDNA fraction fell, with depth at all exons best; at 0.0001-0.001 ctDNA fraction many AUROCs approached 0.5. The values are shown only in Figure 6B and are not stored as results. (Results P15-P17; Figure 6; Methods P31)
- Relevance of ctdnalit-20261011-helzer2025-protocol-grail-full to "Which fragmentomics workflow detects tumour-derived plasma DNA under realistic low tumour fractions and fixed false-positive constraints?": Assessed by Helzer et al. 2025 Razavi et al. 2019 GRAIL cohort, full panel: multinomial phenotype AUROC (ctdnalit-20261011-helzer2025-source-article: Results P5-P8; Methods P23-P31; ctdnalit-20261011-helzer2025-source-supplementary-information: Supplementary Table S1)
- Relevance of ctdnalit-20261011-helzer2025-protocol-uw-full to "Which fragmentomics workflow detects tumour-derived plasma DNA under realistic low tumour fractions and fixed false-positive constraints?": Assessed by Helzer et al. 2025 UW cohort, full panel: multinomial phenotype AUROC (ctdnalit-20261011-helzer2025-source-article: Results P5-P8; Methods P23-P31; ctdnalit-20261011-helzer2025-source-supplementary-information: Supplementary Table S2)
Models, benchmarks and other records
Methods (14)
- All panel fragmentomic metrics combined
- End-motif diversity score at each panel exon
- End-motif diversity score at first coding exons
- Fragment-length bin proportions at each panel exon
- Fragment-size entropy at cancer-specific open chromatin
- Fragment-size entropy at transcription factor binding sites
- Fragment-size Shannon entropy at each panel exon
- Fragment-size Shannon entropy at first coding exons
- Griffin
- Normalised fragment read depth at each panel exon
- Normalised fragment read depth at first coding exons
- Normalised fragment read depth per gene
- Small-fragment proportion at each panel exon
- Small-fragment proportion at first coding exons
Configurations (14)
- All panel fragmentomic metrics combined, GLMnet multinomial classifier (Helzer et al. 2025)
- End-motif diversity score at each panel exon, GLMnet multinomial classifier (Helzer et al. 2025)
- End-motif diversity score at first coding exons, GLMnet multinomial classifier (Helzer et al. 2025)
- Fragment-length bin proportions at each panel exon, GLMnet multinomial classifier (Helzer et al. 2025)
- Fragment-size entropy at cancer-specific open chromatin, GLMnet multinomial classifier (Helzer et al. 2025)
- Fragment-size entropy at transcription factor binding sites, GLMnet multinomial classifier (Helzer et al. 2025)
- Fragment-size Shannon entropy at each panel exon, GLMnet multinomial classifier (Helzer et al. 2025)
- Fragment-size Shannon entropy at first coding exons, GLMnet multinomial classifier (Helzer et al. 2025)
- Griffin, GLMnet multinomial classifier (Helzer et al. 2025)
- Normalised fragment read depth at each panel exon, GLMnet multinomial classifier (Helzer et al. 2025)
- Normalised fragment read depth at first coding exons, GLMnet multinomial classifier (Helzer et al. 2025)
- Normalised fragment read depth per gene, GLMnet multinomial classifier (Helzer et al. 2025)
- Small-fragment proportion at each panel exon, GLMnet multinomial classifier (Helzer et al. 2025)
- Small-fragment proportion at first coding exons, GLMnet multinomial classifier (Helzer et al. 2025)
Protocols (8)
- Helzer et al. 2025 Razavi et al. 2019 GRAIL cohort, FoundationOne Liquid CDx gene subset: multinomial phenotype AUROC
- Helzer et al. 2025 Razavi et al. 2019 GRAIL cohort, full panel: multinomial phenotype AUROC
- Helzer et al. 2025 Razavi et al. 2019 GRAIL cohort, Guardant360 CDx gene subset: multinomial phenotype AUROC
- Helzer et al. 2025 Razavi et al. 2019 GRAIL cohort, Tempus xF gene subset: multinomial phenotype AUROC
- Helzer et al. 2025 UW cohort, FoundationOne Liquid CDx gene subset: multinomial phenotype AUROC
- Helzer et al. 2025 UW cohort, full panel: multinomial phenotype AUROC
- Helzer et al. 2025 UW cohort, Guardant360 CDx gene subset: multinomial phenotype AUROC
- Helzer et al. 2025 UW cohort, Tempus xF gene subset: multinomial phenotype AUROC
Datasets (2)
Evaluations (105)
- All Combined on grail foundationone (Helzer et al. 2025)
- All Combined on grail full (Helzer et al. 2025)
- All Combined on grail guardant360 (Helzer et al. 2025)
- All Combined on grail tempus xf (Helzer et al. 2025)
- All Combined on uw foundationone (Helzer et al. 2025)
- All Combined on uw full (Helzer et al. 2025)
- All Combined on uw guardant360 (Helzer et al. 2025)
- All Combined on uw tempus xf (Helzer et al. 2025)
- All Exons Depth on grail foundationone (Helzer et al. 2025)
- All Exons Depth on grail full (Helzer et al. 2025)
- All Exons Depth on grail guardant360 (Helzer et al. 2025)
- All Exons Depth on grail tempus xf (Helzer et al. 2025)
- All Exons Depth on uw foundationone (Helzer et al. 2025)
- All Exons Depth on uw full (Helzer et al. 2025)
- All Exons Depth on uw guardant360 (Helzer et al. 2025)
- All Exons Depth on uw tempus xf (Helzer et al. 2025)
- All Exons MDS on grail foundationone (Helzer et al. 2025)
- All Exons MDS on grail full (Helzer et al. 2025)
- All Exons MDS on grail guardant360 (Helzer et al. 2025)
- All Exons MDS on grail tempus xf (Helzer et al. 2025)
- All Exons MDS on uw foundationone (Helzer et al. 2025)
- All Exons MDS on uw full (Helzer et al. 2025)
- All Exons MDS on uw guardant360 (Helzer et al. 2025)
- All Exons MDS on uw tempus xf (Helzer et al. 2025)
- All Exons SE on grail foundationone (Helzer et al. 2025)
Evidence
Source checking verifies the cited claim or transcription. It does not establish independent reproduction.
Evidence table
Inspect claims, sources and review details
Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.
One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.
21 evidence rows matching the loaded filters
| Property and statement | Original source and location | Review and provenance |
|---|---|---|
| Archive note gzip -n -9 copy of the exact bytes in artifacts/helzer2025-article.xml.gz (CC BY 4.0) Source metadata | Analysis of cfDNA fragmentomics metrics and commercial targeted sequencing panels No field-specific location recorded Version: Nature Communications 16, published online 2025-10-14; Europe PMC full-text JATS XML of PMC12521513 | catalogued No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Archive sha256 d3f262037df5f2aabc36cbe9e3b80ea994319a32f56da881fc332f36381c5dc2 Source metadata | Analysis of cfDNA fragmentomics metrics and commercial targeted sequencing panels No field-specific location recorded Version: Nature Communications 16, published online 2025-10-14; Europe PMC full-text JATS XML of PMC12521513 | catalogued No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Artifact SHA-256 48e63b9225dd6b4b8f67e25c58a026e9a7183eb790c5900e752a6d2f70ead835 Source metadata | Analysis of cfDNA fragmentomics metrics and commercial targeted sequencing panels No field-specific location recorded Version: Nature Communications 16, published online 2025-10-14; Europe PMC full-text JATS XML of PMC12521513 | catalogued No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Artifact url https://www.ebi.ac.uk/europepmc/webservices/rest/PMC12521513/fullTextXML Source metadata | Analysis of cfDNA fragmentomics metrics and commercial targeted sequencing panels No field-specific location recorded Version: Nature Communications 16, published online 2025-10-14; Europe PMC full-text JATS XML of PMC12521513 | catalogued No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Doi 10.1038/s41467-025-64153-z Source metadata | Analysis of cfDNA fragmentomics metrics and commercial targeted sequencing panels No field-specific location recorded Version: Nature Communications 16, published online 2025-10-14; Europe PMC full-text JATS XML of PMC12521513 | catalogued No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Licence CC-BY-4.0 Source metadata | Analysis of cfDNA fragmentomics metrics and commercial targeted sequencing panels No field-specific location recorded Version: Nature Communications 16, published online 2025-10-14; Europe PMC full-text JATS XML of PMC12521513 | catalogued No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Media type application/xml Source metadata | Analysis of cfDNA fragmentomics metrics and commercial targeted sequencing panels No field-specific location recorded Version: Nature Communications 16, published online 2025-10-14; Europe PMC full-text JATS XML of PMC12521513 | catalogued No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Publication status peer_reviewed Source metadata | Analysis of cfDNA fragmentomics metrics and commercial targeted sequencing panels No field-specific location recorded Version: Nature Communications 16, published online 2025-10-14; Europe PMC full-text JATS XML of PMC12521513 | catalogued No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Retrieved at 2026-10-11T21:40:59Z Source metadata | Analysis of cfDNA fragmentomics metrics and commercial targeted sequencing panels No field-specific location recorded Version: Nature Communications 16, published online 2025-10-14; Europe PMC full-text JATS XML of PMC12521513 | catalogued No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Scope note The authors (University of Wisconsin) previously published first-exon fragment-size entropy on targeted panels (their reference 19) and here re-implement other groups' whole-genome fragmentomic metrics on panel exons. They state that the study compares metrics and does not produce a locked prediction model. Source metadata | Analysis of cfDNA fragmentomics metrics and commercial targeted sequencing panels No field-specific location recorded Version: Nature Communications 16, published online 2025-10-14; Europe PMC full-text JATS XML of PMC12521513 | catalogued No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
Sources and history
Release 2026-11-21-c8bea25e5abb · Record review: source checked
Primary source retrieved and hashed for the 2026-10-11 plasma ctDNA literature pass.
Technical metadata and extraction receipts
Stable ID: ctdnalit-20261011-helzer2025-source-article
- areas
- dna-genomes
- contexts
- clinical_research
- url
- https://doi.org/10.1038/s41467-025-64153-z
- artifact url
- https://www.ebi.ac.uk/europepmc/webservices/rest/PMC12521513/fullTextXML
- version
- Nature Communications 16, published online 2025-10-14; Europe PMC full-text JATS XML of PMC12521513
- retrieved at
- 2026-10-11T21:40:59Z
- artifact sha256
- 48e63b9225dd6b4b8f67e25c58a026e9a7183eb790c5900e752a6d2f70ead835
- doi
- 10.1038/s41467-025-64153-z
- publication status
- peer_reviewed
- licence
- CC-BY-4.0
- media type
- application/xml
- source locator
- Full artifact bytes; per-record locators on each record. 'Pn' is the zero-based index of the <p> element in document order in this JATS XML, front matter included.
- archive sha256
- d3f262037df5f2aabc36cbe9e3b80ea994319a32f56da881fc332f36381c5dc2
- archive note
- gzip -n -9 copy of the exact bytes in artifacts/helzer2025-article.xml.gz (CC BY 4.0)
- scope note
- The authors (University of Wisconsin) previously published first-exon fragment-size entropy on targeted panels (their reference 19) and here re-implement other groups' whole-genome fragmentomic metrics on panel exons. They state that the study compares metrics and does not produce a locked prediction model.